meta-Tyrosine (m-Tyr) is a non-proteinogenic isomer of p-tyrosine (Tyr) and is an antimetabolite of proteinogenic amino acid phenylalanine (Phe). This compound can be found in animal and plant cells.
The direct mode of action linked to m-Tyr toxicity is its incorporation into the proteins [9]. In Escherichia coli incorporation occurs through the binding of m-Tyr to the tRNAPhe [10]. As was shown for bacteria and human cells the cytoplasmic or mitochondrial aminoacyl-tRNA synthetases are prone to catalyzing the binding of tRNAPhe with m-Tyr [11], thus Tyr isomers at higher concentration compete with Phe, for tRNAPhe [12]. The incorporation of m-Tyr into plant proteins was also demonstrated for 5-days old Arabidopsis seedlings [13].
The toxicity of m-Tyr might be overcome by the Phe application [14]. The mechanism of recovery effect is most probably based on the competition between Phe and m-Tyr [15]. m-Tyr toxicity is also linked to altered reactive oxygen species (ROS) metabolism including accumulation of carbonylated proteins [14][16]. Besides alteration of ROS metabolism, m-Tyr has an impact on reactive nitrogen species (RNS) content [16][17] .
In humans, elevated concentration of this Tyr isomer occurs in neurodegenerative diseases and diseases associated with oxidative stress and/or ageing: diabetes, artherosclerosis and others [18]. Moreover, m-Tyr can play a significant role in the cancer cells in animals. The concomitant tumor resistance is the phenomenon of inhibition of secondary tumor implants or metastasis development in hosts, that already are affected by the primary tumor [19]. m-Tyr and o-Tyr were found to be a factor leading to that resistance as they were discovered in the serum of tumor-bearing mice (Mus musculus). Administration of these NPAAs inhibited the growth of tumors in the murine models of cancer [20]. As was discussed, while secondary tumors are inhibited by circulating m-Tyr, the primary tumor microenvironment is protected by an accumulation of AA with counteracting properties (i.e. Phe) [21]. The primary tumor affected ROS generation resulting in the increased m-Tyr and o-Tyr content [20]. This effect was observed in different human tumors type (prostate tumor, lung anaplastic, and nasopharyngeal carcinoma), where the application of m-Tyr led to inhibition of cancer proliferation [22]. The treatment of cancer cells with m-Tyr induced the autophagy, however, the application of Phe reversed the toxic effect of m-Tyr on secondary cancer growth [20][22]. Studies on the key role of non-proteinogenic Tyr isomers in the mechanism of concomitant tumor resistance have shown an antiproliferative and anti-metastaic effect of m-Tyr [20][21][22]. Moreover, m-Tyr can stop the growth of cells from tumor fragments that could have remained post surgery.
Phe might overcome the toxic effect of m-Tyr. Increased Phe level may be achieved by the inhibition of the activity of Phe hydroxylase (the enzyme responsible for Phe catabolism). On the other hand, the degradation of Tyr isomers may occur by the higher activity of tyrosine aminotransferase (Tyr-AT) – first enzyme in the Tyr catabolism pathway [18].